Trial intelligence / Profile preview

Phase 3 study of zanubrutinib plus anti-CD20 antibody vs lenalidomide plus rituximab in relapsed/refractory follicular or marginal zone lymphoma

CTR20232545Phase 3Active

Sponsor

BeiGene

Start

Nov 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1